WuXi AppTec Completes A-Share Repurchase Program for 2025 to Cancel All Shares

WuXi AppTec Wraps Up Second A-Share Repurchase in 2025

In a significant move aimed at bolstering shareholder confidence, WuXi AppTec Co., Ltd., a prominent global provider of research and development (R&D) and manufacturing services for the pharmaceutical and life sciences industries, has completed its second A-share repurchase program of 2025. The company announced on August 27, 2025, that all repurchased shares, valued at RMB1.0 billion, will be canceled.

This repurchase program comes after an approval granted during the Annual General Meeting held on April 29, 2025. The program was put in place to enhance the overall market value of the company and protect shareholders’ interests amid a fluctuating market environment. WuXi AppTec successfully acquired a total of 11,860,809 A-shares, which amounts to approximately 0.40% of its total share capital as of August 27.

The period for this repurchase initiative spanned from June 26 to August 26, 2025. According to the company, all A-shares repurchased under this program are set for cancellation on August 28, 2025. This action is a part of WuXi AppTec’s strategic approach to improve shareholder rewards, including substantial cash dividends, which collectively amount to RMB5.84 billion this year, representing more than 60% of the net profit attributed to the owners in 2024.

Moreover, this year, WuXi AppTec has completed a cumulative total of RMB2.0 billion in A-share repurchases, a proactive measure reflecting its dedication to shareholder value enhancement. The repurchase initiative has illuminated the company’s intentions to prioritize financial health and shareholder profits amidst challenging market dynamics.

WuXi AppTec operates a diversified platform that supports the pharmaceutical sector globally, providing tailor-made services that span R&D to manufacturing. The firm is headquartered in Shanghai, with extensive operations across various regions including North America and Europe. With nearly 6,000 partners in over 30 countries, WuXi AppTec champions healthcare innovation through its unique CRDMO (Contract Research, Development, and Manufacturing Organization) services.

As the healthcare landscape continues to evolve, WuXi AppTec aims to contribute further to advancing breakthroughs for patients. The completion of this A-share repurchase program signifies the company's commitment to forging strong collaborations and ensuring that advancements in drug development and healthcare solutions reach those in need.

Overall, WuXi AppTec stands firm in its vision that every drug can be made and every disease can be treated, fostering continued growth and supporting the healthcare industry with every partnership formed. For more detailed insights regarding the repurchase program and further corporate announcements, visit their official website at www.wuxiapptec.com.